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1. INTRODUCTION 
The immune system is capable of recognizing and rejecting autologous tumor cells. This is 
suggested by reported cases of spontaneous remission of various cancers (1), and the presence of 
infiltrating leukocytes, the majority of which consist of T cells. However, the very existence of 
cancer and its inevitable progression without treatment demonstrates the inefficiency of the 
natural immune defence in combating tumors, and the ability of neoplastic cells to evade 
immune-surveillance. Thus, the major objectives of immunotherapeutic approaches to the 
treatment of cancer rely on the ability to augment adaptive and natural immune responses against 
malignant cells. 
 
During the last decade a great deal of attention has been paid to the role of dendritic cells (DCs) 
in the development of immune responses; the ultimate aim being to provide a novel means of 
cancer therapy for patients. DCs directly isolated from patients' blood have already been shown 
to be effective in promoting anti-tumor immunity in pilot clinical trials (2), and such approaches 
are likely to be effective in patients who have completed conventional anti-tumor therapies 
(surgery, chemotherapy, radiotherapy) and who have minimal residual disease. By reducing 
tumor bulk prior to immunotherapy the degree of tumor “fight back” will be reduced and the 
efficiency of the immune response most likely enhanced. 
 
 1.1 Prostate Cancer-Associated Antigens 
 
Defining the expression of tumor antigens on primary and metastatic prostate cancer is the crucial 
first step in selecting appropriate targets for immune attack (3). Table 1 summarizes the antigens 
or genes over-expressed in the prostate or prostatic cancer tissues. Unfortunately, not all of the 
antigens expressed in cancer tissues are suitable for the development of immunotherapy. They 
  
may, for instance, be poorly immunogenic or occur frequently in normal tissues, implying that 
these antigens could elicit harmful autoimmune reactions. However, some prostate cancer-
associated antigens have been successfully used in dendritic cell-based immunotherapy of 
prostate cancer, for example with cultured autologous DCs pulsed with HLA-A2 peptide derived 
from prostate specific membrane antigen (PSMA) (4). The Phase I study used HLA-A2 peptide 
derived from PSM antigens (PSM-P1 and PSM-P2) and autologous DCs; PSM-P1- and –P2-
pulsed autologous DCs were administered to fifty-one patients with advanced hormone refractory 
prostate cancer. Neither significant acute or chronic toxicity was observed at any of the doses 
used, except for mild to moderate cases of hypotension without pulse change during the time of 
infusion. A total of 107 patients with either local recurrence of prostate cancer after primary 
treatment failure or with hormone-refractory metastasis prostate cancer were treated in a Phase II 
clinical trial. Patients received six infusions of autologous DCs pulsed with PSM-P1 and –P2 
every six weeks. The treatment was well tolerated by all participants. Approximately 30% of the 
trial participants had clinical responses, as defined by the modified National Prostate Cancer 
Project criteria including a 50% reduction in prostate specific antigen (PSA) (2, 4, 5). A 
population of peripheral blood-derived antigen-presenting cells, including DCs, pulsed with 
selected peptides from prostate acid phosphate (PAP) have been shown to induce prostate cancer-
specific CTL in vitro (6). The use of PSA-specific peptides pulsed onto DCs to induce CTL has 
not been reported to date. However, Heiser and co-workers (7) observed that DCs transfected 
with mRNA encoding PSA could stimulate a primary PSA-specific CTL response in vitro. 
 
 1.2 Dendritic Cell Characteristics 
 
DCs, first discovered in 1973 (8), originate from CD34+ progenitor cells in the bone marrow and 
migrate to the different lymphoid and non-lymphoid tissues. Upon exposure to inflammatory 
  
cytokines, DCs capture antigen and up-regulate the expression of histocompatibility and co-
stimulatory molecules (9). At this point DCs are able to migrate from peripheral tissues to 
regional lymph nodes where they present antigen to, and promote the clonal expansion of antigen 
specific T lymphocytes. Final maturation is completed by the interaction of DCs with T helper 
cells recognizing the presented antigen (10). Indeed, evidence suggests that initial priming of 
cytotoxic T lymphocytes requires both presentation of antigen in the context of major 
histocompatibility complex class-I molecules together with an appropriate co-stimulatory signal 
provided by the antigen-presenting cell. Most tumors do not express co-stimulatory molecules; 
therefore transfer of tumor antigen from the tumor to an APC is required for the initiation of 
specific cytotoxic T lymphocyte responses. This transfer of antigen has been termed ‘cross-
priming’, and evidence suggests that DCs play a central role in the process (11); failure of the 
majority of naturally occurring tumors to initiate an effective immune response may, in large, be 
due to the absence of ‘cross-priming’. However, despite the various mechanisms that tumors may 
possess in order to evade immune attack, there are significant data to show that DC-based 
immunotherapy can provide a real and measurable anti-tumor effect. 
 
DCs are therefore antigen-presenting cells capable of initiating primary immune responses (10). 
They display different functional repertoires of cell surface markers at different stages of their 
development. In the “immature” state DCs are very effective in processing native protein 
antigens via MHC class-II restricted as well as the MHC class-I pathways (12, 13, 14). Whole 
purified protein, necrotic cells or apoptotic cells given to immature DCs are then able to elicit 
immune responses which are class-I and class-II restricted (13, 14, 15, 16). Mature DCs are less 
able to capture new proteins for presentation but are much more efficient in presenting MHC 
associated peptides, stimulating resting CD4+ and CD8+ T cells to grow and differentiate. Mature 
  
DCs pulsed with specific tumor peptide are also able to activate either CD4+ or CD8+ specific T-
cell responses (17, 18, 19).  
 
Difficulties in obtaining sufficient numbers of DCs have been solved, and methods have been 
developed to obtain substantial numbers of DCs from proliferating human bone marrow (20) and 
blood (21). This approach is less practical for small samples of human blood where the frequency 
of CD34+ cells is very low (less than 1%). However enrichment and isolation of CD34+ stem 
cells is now a standard procedure for stem cell support following high dose chemotherapy. 
Adequate numbers of CD34+ cells can be positively selected from the blood of patients 3-4 days 
following treatment with G-CSF. However, the most widely used method to generate DCs to 
study their function and potential use in immunotherapy, is to select monocytes present in human 
blood and culture them in vitro in medium containing GM-CSF and IL-4 (21, 22, 23). Cells 
generated in such a manner can be characterized according to their phenotypic and functional 
characteristics, including morphology, cell surface marker expression, phagocytosis and ability to 
activate helper (CD4+) and cytotoxic (CD8+) T-lymphocytes.  
 
Here we present a simple method to generate immature and mature DCs. 
 
For clinical purposes DCs have to be generated without the use of foreign proteins, in particular 
xenogenic proteins present in fetal calf serum (FCS). However we, along with Pietschmann and 
co-workers (24), have found that DCs generated in medium containing 1% autologous serum and 
GM-CSF and IL-4 for 6 days and TNF-α for another two days expressed significantly lower 
CD40, CD1a and CD54 cell surface markers than DCs cultures in FCS-containing medium. 
Culturing DCs in autologous serum instead of 10% FCS induced morphological changes 
including the absence of aggregate formation and a reduced activity in mixed lymphocyte 
  
reaction (MLR) assays. Their ability to phagocytose latex beads was comparable and both were 
capable of inducing T cells proliferation after incubation with 0.5 µg/mL of tetanus toxoid 
protein. 
 
The following methods can be used to generate DCs and assess their phenotypic and functional 
properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2. MATERIALS 
 
2.1 Medium 
 
The medium used throughout the study was RPMI 1640 supplemented with 200 mmol/L L-
glutamine and with the addition of either 10% fetal calf serum (FCS) or 1% autologous serum 
(heat inactivated 56°C for 30 minutes). 
 
2.2 Other Reagents 
 
• Blocking buffer: 1 x PBS + 0.1% bovine serum albumin (BSA) and 0.02% sodium azide, 
stored at room temperature. 
• Sheath fluid: 6.38 g NaCl + 1 g Boric acid + 0.2 g EDTA-2K + 0.2 g sodium tetraborate, 
made up to 1 litre with distilled water and 0.5% formaldehyde added, stored at room 
temperature. 
• Ficoll Hypaque, stored at room temperature. 
• Propidium Iodine, stored at 4ºC. 
• Fluorescence Mounting Media (Dako, Cambridge, U.K), stored at 4ºC. 
• Tetanus Toxoid, Clostridium tétani (Calbiochem, Nottingham, U.K), stored at -80ºC in 
aliquots after reconstitution in sterile distilled water. 
• Tritium labelled thymindine (3H) (Amersham, Biotech, U.K) 
• 1% Paraformaldehyde, stored at 4ºC. 
• FITC-labeled latex beads (Sigma, U.K), stored at room temperature. 
 
  
2.3 Cytokines 
 
All cytokines were aliquoted using PBS + 0.1% BSA and stored at –80ºC. 
• GM-CSF was obtained from R&D Systems (Oxon, U.K) and was stored at 1 x 107 U/mL. 
• IL-4 was obtained from Prepotec (London, U.K) and was stored at 1 x 106 U/mL. 
• TNF-α was obtained from Benderwein (Boehringer Ingelheim, Germany) and stored at 10 
µg/mL. 
 
2.4 Primary Antibodies 
 
All antibodies were aliquoted and stored at -80ºC. 
 
CD14 was obtained from Harlan Sera Lab (Loughborough, U.K); CD83*, CD86* and CD1a* 
were bought from Pharmingen International (Oxford, U.K), and CD11c, CD40, CD54, and 
isotype control IgG1 were bought from Diaclone (I.D.S, Tyne&Wear, U.K). All antibodies were 
FITC-conjugated. MHC class-II an anti-DR antibody was generated from the cell line HB-55, 
obtained from the ATCC. 
* Non-conjugated antibodies 
 
Secondary antibody consisted of a goat anti-mouse FITC-conjugated F(ab)2 fragment and was 
obtained from Sigma, U.K.  
 
Anti-tubuline antibody was obtained from Sigma, U.K. The secondary antibody consisted of an 
anti-IgG mouse antibody PE conjugated and was obtained from Serotec (Oxford, U.K). 
  
 
3. METHODS 
 
3.1 Blood Separation 
 
The blood packs used were obtained from the National Donor Centre at Sheffield, U.K, as a 
leukophoresis pack containing 80 mL of concentrated leukocytes obtained from 300 mL of blood. 
The cells were aspirated from the blood pack and mixed with 80 mL of sterile PBS in a sterile 
glass bottle. 
 
The blood cells were separated using a density gradient on Ficoll Hypaque; 15 mL of diluted 
blood were carefully layered onto 7.5 mL of Ficoll Hypaque contained in a sterile universal. The 
universals were centrifuged at room temperature at 400 g for 30 minutes without brake. The 
plasma layer was removed, placed in a centrifuge tube and heat inactivated by incubation in a 
water bath at 56ºC for 30 minutes, and left to cool at 4°C for an hour or until needed. Finally, the 
plasma sample was centrifuged at 600 g for 10 minutes at 4ºC and the supernatant carefully 
aspirated off and kept at –20ºC in 5 mL aliquots. 
 
The leukocyte layers were carefully removed with a wide ended pipette and placed into separate 
pre-chilled plastic sterile universals. Cold PBS was then added to fill the tubes. The universals 
were centrifuged at 600 g for 15 minutes at 4ºC. The supernatant was centrifuged again under the 
same conditions and the pellet re-suspended in 10 mL of media. The original pellets were 
resuspended in 10 mL of cold PBS and centrifuged at 600 g for 10 minutes at 4ºC. The 
supernatant from all tubes was discarded and the cells re-suspended in 10 mL of RPMI + 
glutamine. Cells from both tubes were pooled before counting (total of 20 mL). Cell counts were 
  
performed using cells diluted first in 0.6% acetic acid to lyse any remaining red blood cells and 
subsequently diluted in trypan blue to exclude dead cells. 
 
3.2 In Vitro Generation of Immature and Mature Dendritic Cells 
 
This method was adapted from Thurner and co-workers (23). The generation of immature and 
mature DCs was obtained after 6 and 8 days in culture respectively. 
 
3.2.1 Generation of Immature Dendritic Cells 
3.2.1.1 Day 0 
Peripheral blood mononuclear cells (PBMC) were plated at 4-5 x 106 cells/mL in media 
containing either 10% FCS or 1% autologous serum in T75 flasks, with the volume not exceeding 
40 mL.  The cells were incubated at 37ºC for 2 hours, non-adherent cells were then removed, 
concentrated by centrifugation at 600 g for 10 minutes at 4ºC, counted and frozen at 1 x 107 
cells/mL of freezing mixture, consisting of 60-70% FCS, 10% DMSO and media (designated T-
lymphocyte fraction). The same volume of the same media as used for the 2 hours incubation was 
added to the adherent cells, which were incubated overnight (o/n) at 37ºC. 
 
3.2.1.2 Day 1 
The majority of the cells became non-adherent and were collected in a 50 mL tube, centrifuged at 
400 g for 5 minutes, re-suspended in media and counted. The cell concentration was then 
adjusted to 1 x 106 cells/mL and 5 mL placed into each well of a 6-well plate and incubated for 
45 minutes at 37ºC. The non-adherent cells were removed and discarded; the wells were washed 
very gently with media and 5 mL of fresh media containing the relevant serum; and 1000 U/mL 
  
GM-CSF and 500 U/mL IL-4 were added to each relevant well and the plates were incubated at 
37ºC. 
 
All these steps of adherence were used to ‘purify’ monocyte-derived DCs. Monocytes, 
macrophages, and B cells can all adhere to the plastic but with different intensity and longevity.  
Monocytes will adhere very quickly to the plastic but will then elute off after o/n incubation but 
will adhere again very quickly to the plastic during the second stage of adherence.  Macrophages 
will also adhere relatively quickly to the plastic but remain firmly adhered even after o/n 
incubation. B-cells may stick after the first adherence stage of 2 hours but will elute off 
permanently after o/n incubation.  
 
3.2.1.3 Day 6 
Immature DCs were apparent in each of the cultures (+FCS or autologous plasma), consisting of 
non-adherent cells showing long digits. The cells from replicate wells were pooled together and 
centrifuged at 400 g and counted. 
 
Some cells were then used for flow cytometric analysis (2 x 105 cells for each cell surface marker 
to be studied) and used in functional assays as detailed below (see Subheadings 3.5 and 3.6). The 
concentration of the remaining cells was adjusted to 0.5 x 106 cells/mL and used for DC 
maturation. 
 
3.2.2 Generation of Immature Dendritic Cells 
 
  
The immature DCs were re-plated at 0.5 x 106 cells/mL per well of a 24-well plate in fresh media 
containing the relevant serum and 1000 U/mL GM-CSF, 500 U/mL IL-4 and 10 ng/mL of TNF-
α.  
 
DCs can revert back to their original form when the cytokines are removed until they have fully 
matured; therefore cytokines need to be replenished (36). 
 
The cells were incubated for a further two days at 37ºC. The mature cells were then harvested 
from the cultures and the level of expression of different cell surface marker was analyzed by 
flow cytometry after staining with a panel of antibodies; cultured cells were also used in two 
functional assays (see Subheadings 3.5 and 3.6). 
 
Figures 1 and 2 show the morphologic and phenotypic differences between DCs generated in 
media containing 1% autologous plasma or 10% FCS, as demonstrated by confocal microscopy 
and flow cytometry. 
 
3.3 Differential Expression of Cell Surface Markers by Dendritic Cells Generated after 6 or 
8 Days of Culture (Flow Cytometry Analysis) 
 
2 x 105 (immature or mature) DCs were placed into individual plastic tubes and washed once in 
2-3 mL of "blocking buffer" to block any unspecific sites. The cells were centrifuged for 5 
minutes at 400 g and the supernatant decanted off, and the tubes were inverted onto a tissue to 
clear any remaining droplets. Primary antibodies were then added to individual tubes and the 
cells placed on ice for 30 minutes. 
 
  
The cells were then washed twice in 2 mL of blocking buffer, and centrifuged at 400 g for 5 
minutes at 4ºC to remove the excess antibody. The secondary antibody was added (unless directly 
conjugated antibody was used) to the cells and the tubes were put on ice for a further 30 minutes. 
Cells were then washed twice with 2 mL of blocking buffer. The supernatant was removed and 
200 µL of sheath fluid were added to each tube; the cells were analyzed by flow cytometry or 
covered with foil and stored at 4°C until analysis (see Figure 2). 
 
3.4 Antigen Presentation Assay 
 
DCs were incubated for 24-48 hours with or without tetanus toxoid (0.5 µg/mL) before co-culture 
with autologous or allogeneic T cells. DCs were plated in triplicate in a 96 well plate (100 µL per 
well), starting at a concentration of 2 x 105 cells/mL and then diluted down. Autologous or 
allogeneic T-cells were removed from liquid nitrogen, washed twice with medium, counted and 
made up to a concentration of 2x106 cells/mL in RPMI medium + relevant serum, then 100 µL 
were added to relevant wells. Plates were incubated for 6 days at 37ºC. Tritiated (3H) thymidine 
was added for the last 18 hours. The cells were harvested onto filter paper, which was transferred 
into scintillation tubes, followed by the addition of 2 mL of scintillation fluid. Counts per minute 
for each well were detected using a gamma spectrophotometer (see Figure 3). 
 
3.5 Phagocytosis Assay 
 
0.5 x 106 cells/500 µL of immature or mature DCs were seeded into chamber slides in duplicate. 
10 µL of a 1/200 dilution of the FITC-labeled latex beads were added to each well and the 
chamber was incubated at 37ºC for 24 hours. The media was then removed and the cells gently 
washed with PBS. Following removal of PBS from each well, the cells were fixed with 500 µL of 
  
1% paraformaldehyde solution for 10 minutes at room temperature, then washed in PBS. 50 µL 
of anti-tubulin (1/200 dilution) antibody was then added to each well for 30 minutes and then 
washed twice (5 minute wash) with PBS to remove the excess of antibody. The cells were then 
stained with propidium iodine (10 µg/mL) for 1 minute and the wells were washed twice again 
with PBS. The plastic chambers on the slides were removed, and Dako immunofluorescence 
mounting medium added to each slide. Coverslips were placed over the chambers, which were 
sealed with nail varnished (see Figure 4). 
 
4. CONCLUSIONS AND DISCUSSION 
 
The potential role of DCs in cancer immunotherapy has been firmly established in experimental 
tumor-therapy models and in a number of human clinical trials (25, 26, 27, 28). DC-based cancer 
vaccines, formulated by loading DCs with antigenic peptides or tumor lysates or through 
genetically modifying DCs prior to in vivo administration represents a potentially powerful 
therapeutic strategy. Genetically modified or peptide pulsed DCs can generate effective immune 
responses to established tumors or subsequent tumor challenge. Autologous DCs from normal 
individuals or patients with prostate cancer transfected with RNA encoding PSA are effective in 
stimulating PSA-specific CTL in vitro, implying that neither natural tolerance to PSA antigens 
nor tumor-mediated T cell anergy represents a barriers for CTL generation against the "self-
antigen" PSA (7). Delivering activated DCs (genetically modified or unmodified) directly into 
the tumor microenvironment was shown to enhance immunity and bypass the requirement for 
selective recruitment and local activation of DCs, which is usually disordered in tumors. DC 
inactivation has been clearly demonstrated in prostate cancer where monocyte maturation to give 
rise to DCs is significantly inhibited, as assessed by the expression of DC markers CD1a and 
CD83 and T cell proliferation (29). We have recently shown, using a murine CT26 tumor model, 
  
that combined intra-tumor injection of disabled infectious single cycle HSV virus encoding 
mGM-CSF (DISC-mGM-CSF) and syngeneic bone marrow derived DCs reduced the tumor 
growth of both primary and distant tumor implants (25). A period of 4-6 hours between the 
injection of DISC-mGM-CSF virus and DCs was required to enhance the therapeutic effect. 
Similar therapeutic efficacy was also reported by others using intratumor injection of DCs 
engineered to secrete IL-12 or modified to express CD40L (30, 31, 32). In order to select the 
appropriate conditions for DCs in therapy the following criteria need to be addressed: antigen 
selection, methods for generation and activation of DCs, introducing (targeting) the antigen into 
either the MHC class-I or class-II processing pathways, and route of administration. 
 
In the present study culturing human adherent PBMC for 6 days in the presence of GM-CSF and 
IL-4 successfully generated DCs using media containing either FCS or autologous serum 
supplements. DCs have to be matured in order to become potent T-cell stimulators. During the 
maturation process a variety of different, specific genes are expressed including genes encoding 
co-stimulatory molecules, MHC class-I and class-II antigens (9); in addition, maturation induces 
the rearrangement of cytoskeleton proteins, adhesion molecules and cytokine receptors (9). A 
series of tests was conducted to evaluate the phenotypic and functional status of the activated 
DCs including MLR, cell surface markers expression, latex beads uptake and antigen processing. 
DCs at Day 6 were considered immature since they were efficient in taking up latex particles, 
necrotic cells and tetanus protein; they expressed low levels of cell surface markers and induced a 
weak stimulation of allogeneic T cells in MLR (results not given). Culturing DCs for a further 2 
days in the presence of TNF-α induced maturation, which was manifested by potent stimulation 
of allogeneic T-cells in MLR, increased expression of CD86, CD40 and CD83, and down 
regulation of bead uptake.  
 
  
Generation of DCs in medium containing human plasma (preferably autologous) is required if 
they are to be used for human therapy. Significant differences in the immunnophenotype, 
macropinocytosis, endocytosis and activity in MLR have been reported for DCs generated in FCS 
versus human plasma (33, 34). In our hands, high yields, increased expression of co-stimulatory 
molecules and cell clustering during the first 3 days of culture were observed when PBMC were 
cultured in media supplemented with 10% FCS but not in 1% autologous plasma. A significant 
increase in the expression of CD1a, CD40 and CD54 was observed in DCs cultured in the 
presence of 10% FCS for 10 days in comparison to those cultured in autologous plasma; in 
addition, similar differences were noticed in functional assays using MLR. 
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TABLE 1:  Antigens or genes over-expressed in the prostate or prostate cancer tissues 
 
Antigen                             Brief description 
PSA                       Prostate specific antigen; 34 kDa glycoprotein 
PSMA                    Prostate specific membrane antigen; 100 kDa membrane glycoprotein 
PSCA                     Prostate stem cell antigen; 123 amino acid protein 
PAP                       Prostate acid phosphatase; 343 amino acid, 41 kDa 
PCTA-1                 Prostate carcinoma tumor antigen; 35 kDa 
Ep-CAM                Transmembrane glycoprotein; 40 kDa 
MUC-1 and 2         Mucin antigens 
GM-2                     Ganglioside antigen 
Thy-1                     Transmembrane glycoprotein with 30% homology to PSCA; 110 kDa 
Bcl-2                      Anti-apoptosis protein 
Tn, sTn, TF            Blood group antigens 
hCG beta                Human chorionic gonadotrophin 
PAGE-1                 X chromosome-linked GAGE-like gene 
NY-ESO-1             CT antigen 
p53                         Tumor suppressor protein 
Survivin                 Anti-apoptosis protein 
 
 
 
 
 
 
  
Figure legends: 
 
Figure 1:  Dendritic cells generated in media containing either 10% FCS (A) or autologous (B) 
serum 
 
Adherent PBMC were cultured for 6 days in RPMI containing 1000 U/mL of GM-CSF and 500 
U/mL of IL-4 eith either 10% FCS (A) or 1% autologous serum (B). Cells were observed under 
different magnifications (x 10, x 20 and x 40). Cells cultured with FCS showed clear cluster 
formation. 
 
Figure 2:  Cell surface marker expression on immature dendritic cells (A) and mature dendritic 
cells (B) 
 
Cell surface marker expression was detected on immature (A) or mature (B) dendritic cells 
generated with either 10% FCS or 1% autologous serum using an FITC-conjugated antibody 
(CD11c, CD54) or non-conjugated antibody (CD1a, CD83, CD86, HLA-DR) followed by an 
FITC-conjugated goat anti-mouse F(ab)' fragment. Analysis of the samples was by flow 
cytometry. 
 
Figure 3:  T cell proliferation in response to allogeneic and autologous dendritic cells 
 
Dendritic cells generated with either 10% FCS or 1% autologous serum, were co-cultured with 
autologous or allogeneic T cells for 6 days. 20 µL of 0.37 Mbq/mL of Tritiated thymadine was 
then added to each well for the last 18 hours of culture. Both DC populations were able to induce 
an allogeneic T cell proliferation response but no or very little autologous T cell proliferation. 
  
 
Figure 4:  T cell proliferation in response to dendritic cells incubated with 0.5 µg/mL tetanus 
toxoid 
 
Dendritic cells generated with either 10% FCS or 1% autologous serum were incubated o/n with 
0.5 µg/mL of tetanus toxoid protein and then co-cultured with increasing numbers of autologous 
T cells for 6 days. 20 µL of 0.37 Mbq/mL of Tritiated thymadine was then added to each well for 
the last 18 hours of culture. Both DC populations were able to induce autologous T cell 
proliferation when 0.5 µg/mL tetanus toxoid was used. 
 
Figure 5:  Beads uptake by immature dendritic cells (A and B) or mature dendritic cells (C) 
 
Dendritic cells cultured for 6 days (A & B) or 10 days (C) were incubated o/n at 37oC with FITC-
labeled latex beads (0.2 µm). Nuclei were stained with ethidium bromide and cytoskeleton with a 
mouse anti-tubulin antibody followed by a PE-conjugated anti-mouse antibody. Examination by 
confocal microscopy showed the beads (in green) inside the majority of immature dendritic cells 
(A & B) but only in very few matured DC (C). 
  
Figure 1: Dendritic cells generated in media containing either 10% FCS (A) or autologous 
serum (B) 
 
Figure A Figure B 
  
Figure 2: Cell Surface Marker Expression on Immature 
Dendritic Cells (A) and Mature Dendritic Cells (B) 
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Figure 3: T Cell Proliferation in Response to Allogeneic and 
Autologous Dendritic Cells 
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Figure 4: T Cell Proliferation in Response to DC Incubated 
with 0.5mg/ml Tetanus Toxoid 
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Figure 5: FITC-labelled latex beads uptake by immature (A&B) or mature (C) 
dendritic cells 
Figure B: Day 7 10% Blood pack Figure A: Day 7 1% Blood pack 
Figure C: Day 10 Matured cells fresh blood 10% 
 
